91810
document
[ Treatment of irresectable hepatocellular carcinoma with repeated transient dearterialization ] . A joint clinical prospective study between SUMS and Lund university was reported . 40 patients with the irresectable hepatocellular carcinoma ( HCC ) admitted to the department of HPB surgery in the First Affiliated Hospital of SUMS were randomized into two groups : ( 20 each ) from Feb. 1994 to April , 1995 . The patients were treated with hepatic artery ligation ( HAL ) and repeated transient dearterialization ( RTD ) respectively . Postoperative response to treatment , liver function change ( ALT ) , AFP , imaging examination of the tumor , patient 's survival were evaluated . It has been shown that RTD is superior to HAL in terms of the objective response to the therapy , reduction of tumor size , patient 's symptom relief , liver function and AFP changes and patient 's survival . In the RTD group , the effective rate was 70 % , the mean survival time was 8.2 months , and the 6-month survival rate was 79.7 % . In HAL group , the effective rate was only 5 % , the mean survival time was 5.1 months , 6 months survival rate was 35.8 % . It has been postulated that RTD may prevent the rapid development of collateral circulation and increase the production of oxygen-derived free radicals , which may be the responsible factors for the ischemic treatment of hepatic tumours . We consider that RTD would be a promising polliative method for HCC .
91811
Intervention_Surgical
repeated transient dearterialization ]
91812
Intervention_Surgical
hepatic artery ligation ( HAL )
91813
Intervention_Physical
and
91814
Intervention_Surgical
repeated transient dearterialization ( RTD )
91815
Intervention_Surgical
RTD
91816
Intervention_Surgical
RTD
91817
Intervention_Surgical
RTD
91818
Intervention_Surgical
RTD
91819
Outcome_Physical
liver function change ( ALT ) , AFP , imaging examination of the tumor
91820
Outcome_Mortality
patient 's survival
91821
Outcome_Physical
tumor size
91822
Outcome_Physical
symptom relief
91823
Outcome_Physical
liver function
91824
Outcome_Physical
AFP
91825
Outcome_Mortality
survival
91826
Outcome_Physical
effective rate
91827
Outcome_Mortality
survival time
91828
Outcome_Mortality
survival rate
91829
Outcome_Physical
effective rate
91830
Outcome_Mortality
survival time
91831
Outcome_Mortality
survival rate
91832
Outcome_Physical
production of oxygen-derived free radicals
91833
Participant_Condition
irresectable hepatocellular carcinoma
91834
Participant_Sample-size
40
91835
Participant_Condition
irresectable hepatocellular carcinoma
91836
Participant_Sample-size
20